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Abstract
Background: Cats are definitive hosts of Toxoplasma gondii and play an essential role in the epidemiology of this
parasite. The study aims at clarifying whether cats are able to develop specific antibodies against different clonal
types of T. gondii and to determine by serotyping the T. gondii clonal types prevailing in cats as intermediate hosts in
Germany.
Methodology: To establish a peptide-microarray serotyping test, we identified 24 suitable peptides using serological
T. gondii positive (n=21) and negative cat sera (n=52). To determine the clonal type-specific antibody response of
cats in Germany, 86 field sera from T. gondii seropositive naturally infected cats were tested. In addition, we
analyzed the antibody response in cats experimentally infected with non-canonical T. gondii types (n=7).
Findings: Positive cat reference sera reacted predominantly with peptides harbouring amino acid sequences specific
for the clonal T. gondii type the cats were infected with. When the array was applied to field sera from Germany,
98.8% (85/86) of naturally-infected cats recognized similar peptide patterns as T. gondii type II reference sera and
showed the strongest reaction intensities with clonal type II-specific peptides. In addition, naturally infected cats
recognized type II-specific peptides significantly more frequently than peptides of other type-specificities. Cats
infected with non-canonical types showed the strongest reactivity with peptides presenting amino-acid sequences
specific for both, type I and type III.
Conclusions: Cats are able to mount a clonal type-specific antibody response against T. gondii. Serotyping revealed
for most seropositive field sera patterns resembling those observed after clonal type II-T. gondii infection. This finding
is in accord with our previous results on the occurrence of T. gondii clonal types in oocysts shed by cats in Germany.
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Introduction
Toxoplasma gondii is a zoonotic obligate intracellular
parasite which causes toxoplasmosis in humans and animals.
Felids are definitive hosts of this parasite and almost all warm-
blooded mammals including humans and cats [1,2] can serve
as intermediate hosts.
The population of T. gondii in Europe and North America is
dominated by three clonal types (I, II and III), whereas the
majority of characterized isolates from South America and
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Africa are genetically different from these canonical types. Most
of the genotypes observed in Brazil are regarded as non-
canonical or “atypical”. PCR-RFLP revealed mainly
combinations of type I and III specific alleles [3]. This, however,
does not mean that they represent sexual recombinants
derived from canonical types but should rather be regarded as
evolutionary separate lineages [4-6].
The T. gondii clonal type is regarded as a key-factor
responsible for the clinical appearance of toxoplasmosis in
outbred mice [7]. There is growing evidence that this may also
apply to other intermediate hosts including humans [6,8,9].
Canonical and non-canonical T. gondii were associated with
certain clinical appearances in humans [10-12]. However, the
geographical distribution and dominance of particular T. gondii
types as well as host genetic and immunity related factors may
have biased prior studies [13-15]. For ocular toxoplasmosis, for
example, it was demonstrated that most cases in South
America were caused by non-canonical T. gondii [16], whereas
a predominance of T. gondii type II was found in France
[17,18]. However, Gilbert et al. (2008) [16] demonstrated that
congenitally infected Brazilian children were five times more
likely to develop ocular toxoplasmosis with more severe
symptoms than congenitally infected children from Europe.
McLeod et al. (2012) observed both T. gondii serotypes, II and
NE-II (i.e., not exclusively serotype II), in cases of congenital
toxoplasmosis in North America. However, the T. gondii
serotype NE-II was more frequently found in certain
demographic groups and was statistically associated with more
severe cases of congenital toxoplasmosis [9]. These findings
may suggest that the severity of human toxoplasmosis could
be influenced by the genotype of T. gondii that has caused the
infection. It is therefore epidemiologically relevant to determine
the T. gondii types dominating in particular geographical areas
and to compare the T. gondii types prevailing in clinical cases
of toxoplasmosis in humans and animals [19].
The majority of typing studies on T. gondii in cats were
performed by using DNA-dependent techniques [20-24].
However, most T. gondii DNA samples were obtained either
from tissues/tissue cysts from euthanized cats or from oocysts
isolated from feline fecal samples. It is difficult to obtain
sufficient amounts of parasite DNA from host tissues and fluids
even in cases of clinical toxoplasmosis. T. gondii DNA from
subclinical cases – which would be of utmost importance for
epidemiological studies on potential type-related effects – are
not available. Serotyping allows not only the inclusion of
clinical, but also of subclinical cases. This explains why typing
T. gondii infections via the antibody response is attractive and
has prompted a number of studies in the past.
T. gondii infection causes a strong and often persistent
humoral immune response with detectable antibody titers,
independent of the clinical manifestations in the infected host
[25,26].
Some of the T. gondii antigenic proteins are presenting
sequence differences in the polypeptides expressed by
different clonal types [10,27,28]. Kong et al. (2003) [10]
demonstrated that the humoral response against T. gondii is
partially type-specific, when the sites of clonal type-specific
polymorphisms are used as peptide antigens. Based on these
results several studies on the serotyping of T. gondii in humans
using polymorphic synthetic peptides have been performed.
The results suggested that it is possible to distinguish between
type II- and non-type II-infection [10,27,29-32]. Xiao et al.
(2009) identified peptides that could be also used to distinguish
between type III- and type I-infections [31].
Cats play an important role in the epidemiology of T. gondii
infection because they are definitive hosts of the parasite. They
can excrete large numbers of environmentally resistant
oocysts, which represent after sporulation one of the main
infection sources for intermediate hosts [33]. Most of the T.
gondii from cats were genetically characterized by PCR-RFLP
and sequencing [34-37] after isolation via mouse bioassay
using infected cat tissues or oocysts from faecal samples
[20,21]. Since T. gondii infection in cats is normally
asymptomatic, it is difficult to isolate the parasite or to detect
oocyst shedding in healthy cats. However, infected cats usually
develop antibodies against T. gondii within approximately 2
weeks after infection [33,38,39]. Consequently, serotyping
could be an alternative method to estimate the prevalence of T.
gondii types in cats. It was unknown whether serotyping of T.
gondii in cats is possible. We therefore first investigated if cats
were able to mount a specific serological response against
canonical clonal types of T. gondii. A synthetic peptide-
microarray was established and used to determine the T.
gondii serotype of naturally infected cats in Germany.
Polymorphic peptides identified for serotyping in cats could
also be suitable for serotyping in other species including
humans.
Materials and Methods
Ethics Statement
All experiments in cats and mice carried out in USA had
been approved by Beltsville Area Animal Care and Use
Committee (BAACUC).
Experimental infection of cats carried out in Iran was
followed as described by the Iranian animal rights organization
[40] and was approved with respect to animal rights by the
Ethic Committee of the Deputy for Research and High
Education Affairs of the Veterinary Faculty of Shahrekord
University (No. 122.5938-9). Details on the experimental
infections conducted in Iran and the serological results of the
kittens were published elsewhere [41]. Sera from cats in
Germany and Switzerland were collected for routine veterinary
diagnostic purposes and not for the purpose of research;
consequently no ethical approval was needed.
Selection of peptide sequences
A total of 101 T. gondii polymorphic peptide sequences, i.e.
peptide sequences, which differed for at least two of the three
canonical types I, II and III, were chosen to detect clonal type-
specific antibodies in sera from T. gondii-infected animals.
These included 54 peptide sequences from 15 T.
gondii immunogens previously reported as clonal type-specific
[10].
In addition, 47 of the 101 polymorphic peptides were
selected based on T. gondii amino acid sequences partially
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published in Genbank. They included peptides from the dense
granule proteins GRA6 (AAF60334; AAF60336; AAF60337)
[27,42], GRA5 (sequences were taken from a publication, [27]),
and GRA7 (ABE69193; EU157141; DQ459455) [43,44] as well
as the surface antigen SAG2A (AAK50636; AAK50637;
AAK50638; AAF79155) [45,46]. For the identification of
polymorphic, i.e. type-specific amino acid (aa) sequences,
protein sequence analysis and alignment was performed using
the “MegAlign” tool provided by DNAStar software (DNASTAR,
Inc; Madison; Wisconsin; USA). Polymorphic, 15 aa long
peptide sequences containing B-cell epitopes were selected
using the “Protean” tool of DNAStar (DNAStar Inc; Madison;
Wisconsin; USA). Propensity scale methods and cut-offs
implemented in this program were used to identify aa regions
with potential B cell epitopes according to following criteria: (i)
predicted alpha-helical structure (as determined by “Garnier-
Robson plots” [47]), (ii) presence of proline residues, (iii)
substantial content of hydrophilic amino acids (as determined
by “Kyte-Doolittle hydropathy plots” [48]), (iv) high “antigenic
index” using “Jameson and Wolf plots” [49] integrating flexibility
parameters with hydropathy/solvent accessibility values, and
(v) a high surface probability (“Emini’s surface probability plots”
[50]), based on side-chain solvent accessibility values of the
individual aa. Information on all peptide sequences selected for
this study is presented in Table S1.
Cat sera
Sera from cats infected with canonical T. gondii.  In all,
17 cat sera specific for clonal type I, 3 sera specific for clonal
type II and one serum specific for clonal type III were available
as positive reference standards for the validation of peptides
for T. gondii serotyping in cats. Sera obtained from cats
inoculated with tissue cysts of mouse virulent non-canonical T.
gondii isolates (n=7) were also included.
The serological status of the reference sera was determined
in an immunofluorescence antibody test (IFAT) and by
immunoblotting using T. gondii surface antigen 1 (TgSAG1) as
antigen (as described below).
Except one type II serum, which was obtained from an
immunocompetent 10-year-old male cat that had died of
systemic toxoplasmosis and from which a T. gondii strain
presenting a clonal type II specific allele pattern in PCR-RFLP
was isolated (in this study referred to as TgCatSw1) [51] (Table
S2), all positive reference standards derived from experimental
infections as described in the following.
Sera from cats infected per os with tissue cysts at the Animal
Parasitic Diseases Laboratory, Beltsville Agricultural Research
Centre, Maryland, USA: All cats fed with tissue cysts were bled
prior to infection and had no antibodies in a 1:25 serum dilution
tested by the MAT [52]. The number of tissue cysts in the
inocula was unknown as the cats were fed whole infected
tissues. The cats were obtained from a T. gondii-free cat
colony as described previously [37]. They were 3-5 months old
at the time of the experiment [39].
Three cats were infected with T. gondii type I tissue cysts
from the CT1 strain, two with the GT1 strain and one cat with
the RH strain. Sera from these cats were collected on days 22,
35, 25, 29, 34 and 43 post infection. Two cats were
experimentally inoculated with T. gondii type II tissue cysts of
the TgSdCo1 T. gondii isolate and ME49 strain [53,54]. Sera
from these animals were collected on days 49 and 29 post
inoculation respectively. To validate clonal type III-specific
peptides, a single serum was available from a cat
experimentally infected with tissue cysts from mice infected
with the VEG strain [55]. The serum was collected on day 23
post infection (Table S2).
Sera from cats experimentally infected with tachyzoites at
the Veterinary Faculty of Shahrekord University, Iran: Six 45±5-
day-old clinically healthy kittens of both genders were infected
intraperitoneally with 104 T. gondii RH tachyzoites in sterile
PBS as described previously [41]. In five of six kittens infected
with RH tachyzoites, serum samples were collected on days 18
and 26 post infections. From one kitten, only a serum sample
collected on day 26 post infection was available (Table S2).
Sera from cats infected with non-canonical T.
gondii.  Three isolates were from Paraná, Brazil (TgCatBr1, 2,
5) [56] (Table S2). Three cats were experimentally infected
each with one of these isolates at the Animal Parasitic
Diseases Laboratory, Beltsville, Agricultural Research Centre,
Maryland, USA. Sera were collected for further analysis on
days 42 and 30 post infection (Table S2). Further sera were
from three cats infected with T. gondii isolated from a wild black
bear from Alaska (TgBbUS1) [57] and one serum derived from
a cat experimentally infected with T. gondii isolated from a goat
in the USA (TgGoatUS6) [58]. Serum samples within this group
were collected on days 37, 24, 33, 43 and 36 post infection
(Table S2).
Sera from naturally T. gondii seropositive cats.  All field
sera from cats used in this study (n=138) were collected during
serological routine testing for T. gondii at Vet Med Labor
GmbH, Division of IDEXX Laboratories, Ludwigsburg,
Germany. Fifty two serum samples were negative for T. gondii
antibodies in both serological tests (IFAT and TgSAG1-
immunoblot), and were used for the validation of peptides as
part of the negative reference standard in a ROC analysis.
Eighty six samples were seropositive in both serological tests
and further used to determine the clonal types naturally T.
gondii-infected cats from Germany were carrying.
IFAT
The T. gondii strain RH (Sabin, 1941) was cultivated and
used for preparation of IFAT slides as described previously
[58]. The test was performed as described for N. caninum [59]
but with the following modification: Anti-cat IgG [H+L] produced
in goat and coupled to FITC (102-095-003, ImmunoResearch
Laboratories, West Grove, Pennsylvania, USA) diluted 1:50 in
PBS, 0.2% Evans Blue was used to detect primary antibodies.
A reciprocal titer of 200 was used as the positive cut-off titer.
TgSAG1 immunoblot
Native TgSAG1 was affinity-purified as described [58]. The
identity of the purified protein was confirmed using monoclonal
antibodies against TgSAG1 (IgG2a P30/3 [ISL, Paignton, UK]).
Detection of antibodies against TgSAG1 was performed
essentially as described [60] with a few modifications. Briefly,
cat sera were diluted 1:100 and the conjugate (Peroxidase-
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conjugated AffiniPure Goat anti-cat IgG [H+L], 102-035-003,
Jackson ImmunoResearch, West Grove, Pennsylvania, USA)
was diluted 1:500. Reactivity with a 30 kDa band was regarded
as a T. gondii-positive reaction Two sera obtained from an
IFAT-positive and an IFAT-negative cat were used as controls.
Peptide-microarray
Peptides were synthesized and printed on peptide-
microarray slides (i.e. modified glass-slides) by JPT Peptide
Technologies GmbH, Berlin, Germany, essentially as described
[30].
Cat serum samples were processed on peptide-microarrays
as described [61] with a few modifications. Serum samples (60
µl/well), diluted 1:100 in blocking solution (PBS, 0.05% Tween
20, 0.2% I-Block [Applied Biosystems, Bedford, MA, USA]),
were incubated at 37°C for 1 h and washed seven times for 3
min with PBS-T (PBS, pH 7.2; 0.5% Tween 20) at room
temperature. Conjugate (Biotin-SP-conjugated AffiniPure goat
anti-cat IgG, Fc Fragment Specific, 102-065-008, Jackson
ImmunoResearch Laboratories, West Grove, Pennsylvania,
USA) diluted in blocking solution 1:500 (1 µg/ml) was added to
the wells (60 µl/well), incubated at 37°C for 30 min, and
washed as indicated above. CyTm5-conjugated streptavidin
(016-170-084, Jackson ImmunoResearch Laboratories, West
Grove, Pennsylvania, USA) diluted in blocking solution 1:500 (1
µg/ml) was added to the wells (60 µl/Well), incubated at 37 °C
for 30 min and washed as described, followed by three
additional washing steps, 1 min each, with sterile-filtered MilliQ
water. Afterwards, the microarrays were spun dry for 10 s using
a slide spinner (DW-41MA-230, Qualitron Inc/Eppendorf,
Berzdorf, Germany).
Scanning and evaluation of microarrays, as well as data
extraction was performed as described [30].
Microarray data analysis
To analyze the raw data (median of signal intensity) in GPR
(GenePix Results) files, index values (IVs), as well as the
means of the IVs for each peptide triplicate per block (mean
sample index value, MSIV) were recovered as described
previously using R (R version 2.14.1 (2011-07-08) Copyright
(C) 2011; ISBN 3-900051-08-9; http://CRAN.R-project.org/)
[30,61-63]. The peptide-microarrays used in this study failed to
meet the criteria required for submission under MIAME based
public databases, because the data type of biomolecular
interaction and parameters studied, the protocols as well as the
type of information extracted from the microarray experiment
differed from standard DNA microarray experiments
[30,61,64,65]. Therefore MSIVs for all sera and peptides are
presented as supplemental material (Table S3).
Statistical analysis
For statistical analysis and graphical presentation of results,
the R program environment was used (R version 2.14.1
(2011-07-08) Copyright (C) 2011; ISBN 3-900051-08-9; http://
CRAN.R-project.org/ ).
To select peptides appropriate for serotyping and to establish
individual cut-offs for each peptide, a Receiver Operating
Characteristics (ROC) analysis was conducted using the R-
package ‘‘DiagnosisMed’’.
For the ROC based selection of peptides derived from
polymorphic clonal type-specific regions, reactions of reference
sera derived from cats infected with a homologous type of T.
gondii were used as a “positive reference standard”. In
contrast, T. gondii negative sera and sera from cats infected
with a heterologous clonal type of T. gondii were used as a
“negative reference standard”. ROC analysis was performed
using these reference standards and based on literature
information [32,66] peptides with an Area-Under-ROC-Curve
(AUC) value of ≥ 0.7 were considered to have enough
discriminatory power for serotyping [67]; the higher the AUC
the better a peptide discriminates between reference positive
and negative sera. ROC analysis was also used to define
individual peptide-specific cut-offs, at which the sum of
diagnostic sensitivity and specificity for individual peptides
reached its optimum, i.e. was as high as possible. These cut-
offs for individual peptides were used to define positive and
negative peptide reactions, to determine typing sensitivity and
specificity and to determine the proportion of false positive
typing reactions among the T. gondii-positive cat reference
sera infected with a heterologous T. gondii type in relation to
peptide specificity and serologically negative cat sera. Peptides
with a proportion of false positive reactions among these sera
of > 45% were excluded from further analysis. Positive and
negative reactions of the finally selected peptides were used
for further frequency and Post-Hoc-Test (LSD [Least-
Significant-Difference]) of ANOVA analyses.
Frequency analysis (Log-linear model, Chi-Square) for
serotyping data was performed with the R-package “vcd”,
which was also used to visualize the results in mosaic plots as
described previously [28,30,68].
Serum-peptide reactions (mean sample index values,
MSIVs) were cut-off normalized (CN) by subtracting the
peptide-specific cut-off values from MSIV resulting in a value
called CN-MSIV. This was done to achieve a better
visualization of positive and negative serum-peptide reactions,
e.g. positive reactions led to values ≥ 0 and negative results to
values < 0. To perform multiple comparisons of CN-MSIV
means between peptide groups or between single peptides, a
Post-Hoc-Test (LSD [Least-Significant-Difference]) on ANOVA
results was applied using the R package “agricolae” [30,61].
To analyse whether peptide patterns recognized by
individual sera cluster in different groups, we performed
explorative data analysis applying the artificial neural network-
based Selforganizing Kohonen Network/Selforganizing
Kohonen Maps (SOM) method [69-72]. In the present study we
used supervised XY-fused Selforganizing Kohonen Network
analysis to find a relationship between the input data
(measurements of serum-peptide reactions and peptide
groups) presented by X-map and output data (cat sera groups)
presented by Y-map. XY-fused supervised Kohonen network
(XYF-SKN) analysis was applied using the R package
“kohonen” [69,70]. We used a SOM grid of 4×2 units (nodes).
The topology of the grid was hexagonal. The complete data set
was presented 2000 times to the network. For this analysis,
serum-peptide reactions were used with original MSIVs.
Serotyping of Toxoplasma gondii in Cats
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Results
Confirmation of the T. gondii serological status of cat
sera
IFAT was used to determine the serological status of cats.
Within the group of sera regarded as T. gondii negative (n=52),
the reciprocal IFAT titres ranged from <25 to 100. Among the
sera regarded as positive (n=114) reciprocal IFAT titres ranged
from 200 to 51200 (Table 1, Table S3). IFAT results were
confirmed by the TgSAG1 immunoblot. In 114 of 114 (100%)
IFAT positive field and reference sera antibodies to TgSAG1
were detected, while 52 of 52 (100%) of the IFAT negative field
sera were negative in the TgSAG1 immunoblot.
Prediction of 47 novel potential polymorphic epitopes
In addition to 54 polymorphic peptides previously described
[10], 47 novel polymorphic, i.e. type-specific, peptides derived
from GRA5, GRA6, GRA7, SAG2A protein sequences were
selected using a propensity scale method to extend the peptide
panel for the serotyping of T. gondii clonal types by peptide-
microarray using cat sera.
Based on the GRA5 protein sequences available for the
clonal lineages I, II, and III 9 potentially type-specific peptide
sequences were identified (Table S1). Compared to the type I
GRA5 (RH strain), six aa substitutions were observed in type II
GRA5 (K76 strain) and three aa changes in type III GRA5
(VEG strain) [27]. All except one aa substitution in GRA5 were
located in the N-terminal hydrophilic region of GRA5. The
selected GRA5 peptide sequences did not meet all the criteria
mentioned in the Materials and Methods section for the
selection of peptides (Table S1): Proline residues were missing
in all GRA5 peptide sequences, and only three of the selected
GRA5-derived peptides we located in putative α-helical regions
(according to the “Garnier-Robson plot”). The “Jameson-Wolf
antigenicity index” suggested, however, that the chosen
peptides were located in antigenic regions and “Emini’s surface
probability plot” showed a high surface-probability for all the
selected peptide-sequences. All sequences were located in
hydrophilic regions of the GRA5 protein according the “Kyte-
Doolittle hydropathy plots” (Table S1).
In the GRA6 aa sequences, 21 polymorphic positions were
identified. In comparison with type I GRA6 (RH strain), the
protein sequence revealed eight aa substitutions and six aa
insertions in type II (ME49 strain), while seven aa substitutions
were detected in type III GRA6 (NED strain). All peptides met
most selection criteria (Table S1). Only three peptides were
located in a region with α-helical properties. Five peptide
sequences contained no proline residues. The selected
peptides were located at both, C- and N- terminal regions
(Table S1).
For GRA7, 13 polymorphic peptide sequences were
selected. All peptide sequences were located near the C-
terminus. In comparison to GRA7 type I (RH strain), eight aa
substitutions were observed in type II (BEVERLEY strain) and
15 aa substitutions in type III (NED strain) (Table S1). All GRA7
peptides were derived from antigenic, hydrophilic regions. They
were selected from regions putatively located on the protein
surface or in putative α-helical regions. Four peptides lacked
proline residues.
For the SAG2A protein, four polymorphic peptides from the
C-terminal region were chosen. The selected peptide regions
met the criteria of antigenicity, hydrophilicity, surface probability
and presence of proline residues. However, the peptides failed
to present an α-helical structure (Table S1). Peptides were
derived either from a polymorphic protein region common for
clonal types I and III (strains S48, NED) or from a region
specific for clonal type II (strains LGE96-1, BEVERLEY).
Selection of 24 peptides appropriate for T. gondii
serotyping in cats
In total, 101 peptides presenting single type-specific
polymorphisms (I [n=27], II [n=29] and III [n= 21]) as well as
common polymorphisms for two of three clonal types
simultaneously (I/II [n=6], I/III [n=12], II/III [n=6]), were used
initially. For the selection of peptides suitable for T. gondii
serotyping individual peptides were first subjected to a ROC
analysis. Those peptides for which ROC analysis revealed a
diagnostic capacity were further analyzed by ANOVA and LSD-
Post-Hoc-Test.
For each group of peptides specific for a particular clonal
type, an individual set of reference sera was used in ROC
analysis, which included sera from T. gondii serologically
negative cats (n=52) and sera from experimentally-infected
cats (n=21). In the individual ROC analyses, 40 of the 101
analyzed peptides yielded on AUC value ≥ 0.7 (Table S4) and
were thus included in a second phase of selection. In this
phase, peptides were excluded which showed a proportion of
false positive reactions of > 45% either in negative field sera or
in the sera of cats infected with a heterologous T. gondii-type in
relation to peptide specificity (Table S4). Further three peptides
were excluded during ANOVA and LSD-Post-Hoc-Test analysis
because they were either recognized nonspecifically (i.e.
Table 1. Positive and negative TgSAG1 immunoblot reactions versus reciprocal Toxoplasma gondii IFAT titers in feline field
and reference sera (n=166).
 Reciprocal Toxoplasma gondii IFAT titre*
TgSAG1 immunoblot <25 25 50 100 200 400 800 1600 3200 6400 12800 25600 51200 
Negative 12 25 8 7 0 0 0 0 0 0 0 0 0
Positive 0 0 0 0 2 2 5 17 26 15 19 22 6
* Positive reciprocal IFAT cut-off > 200
doi: 10.1371/journal.pone.0080213.t001
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showed significantly higher reaction intensities in heterologous
or negative sera than in sera with homologous specificity) or
there were no statistically-significant differences in reactivity
between the different groups of cat sera according to the LSD-
Post-Hoc-Test.
A total of 24 remaining peptides were recognized by sera
with homologous specificity (Table S4). Diagnostic specificity
using the “negative reference standard”, i.e. the level of
restriction of reactions to sera from animals infected with a
clonal type homologous to the type-specificity of the aa
sequence of this individual peptide, ranked from 60% to 98%.
The proportion of false positive reactions among the sera from
animals infected with a clonal type heterologous to the type-
specificity of the peptide ranged from 0% to 44.4% (Table S4).
The proportion of false positive reactions in serological
negative filed sera ranged from 0% to 40.4% (Table S4).
Diagnostic sensitivity using positive sera from cats infected with
the homologous type of T. gondii in relation to peptide
specificity ranged between 5.9% and 100% (Table S4). The
peptides selected for serological typing were derived from
GRA1, 3, 5, 6, 7 and SAG2A proteins. Nine of the 24 peptides
were novel, while 15 had previously been published [10]. In the
peptide panel established in the present study, the type-
specificities were almost equally distributed over the three
clonal types of T. gondii (type I: 9 peptides, type II: 9 peptides,
type III: 11 peptides). The aa sequences of the 24 peptides
showed the following specificities in detail: type I (n=4), type II
(n=8), type III (n=7), type I/II (n=1) and type I/III (n=4).
Serotyping in cats infected with known T. gondii type
Clonal type I-infected cats.  The mean CN-MSIVs by which
peptides with clonal type I-specific aa sequences (I, I/II, I/III)
were recognized by sera of clonal type I-infected cats (n=17)
were significantly higher than the mean CN-MSIVs by which
peptides with type II- or III-specific, i.e. heterologous aa
sequences were recognized by the same sera (Table 2,
ANOVA, LSD ≥ 0.523, p-value < 0.05). The GRA3-I/III-28
peptide was recognized by the significantly highest MSIVs in
this group (Figure 1 [A]), followed by GRA5-I-41, and GRA6-
I-216 (ANOVA, LSD ≥ 0.926, p-value < 0.05). The lowest anti-
clonal type I-specific reactivity was observed for peptide GRA6-
I-173 (Figure 1 [A]). The diagnostic sensitivity of individual
peptides presenting clonal type I-specificity (I, I/II, I/III) ranged
from 5.9% to 94.1% and the diagnostic specificity from 64.2%
to 98.2% (Table S4).
The prevalence of positive and negative serum-peptide
reactions within the group of type I-infected cats was analysed
using a log-linear model. The resulting contingency tables and
deviations from the hypothesis of independence were
visualized by mosaic plots (Figure 1 [B]). Positive clonal type I-
specific peptide reactions were quantitatively overrepresented
(Pearson residuals > 3, p-value < 0.01) among sera of cats
infected with type I T. gondii. In addition, type I/II- and I/III-
specific peptide reactions were also statistically significantly
overrepresented as indicated by Pearson residuals > 3 (p-value
< 0.01). All type II- and III-specific positive peptide reactions
were underrepresented (Pearson residuals < -2, and < -3, p-
value < 0.05 and 0.01 respectively) among sera from type I-
infected cats (Figure 1 [B]).
Clonal type II infected cats.  Analysis of sera from cats
infected with clonal type II T. gondii (n=3) revealed that
peptides presenting type II-specific aa sequences (II, I/II) were
recognized by significantly higher mean CN-MSIVs as
compared to those peptides with heterologous specificity, i.e.
clonal type I or III (Table 2; ANOVA, LSD ≥ 1.034, p-value >
0.05). The dGRA6-II-214(9) peptide was recognized by the
significantly highest mean of CN-MSIVs (Figure 2 [A]), as
compared to the remaining peptides used for serotyping
(ANOVA, LSD ≥ 1.697, p-value < 0.05). The lowest means of
clonal type II-specific CN-MSIVs were observed in GRA7-
II-225, SAG2A-II-93 and GRA1-II-159. Peptides specific for
clonal type I or III were recognized by markedly lower intensity
as compared to those peptides presenting clonal type II
specificity (ANOVA, LSD ≥ 1.697, p-value < 0.05) (Figure 2
[A]). The diagnostic sensitivity of peptides with clonal type II
specificity (II, I/II) ranged between 66.7% and 100% and their
typing specificity ranged from 60% to 98.6% (Table S4).
Table 2. Means of cut-off normalized mean reaction values in peptide and cat groups analyzed by ANOVA/LSD Post-Hoc-
Test.
Cat groups* (Least significant difference, LSD) Means of CN-MSIV within peptide groups (95% Cl)**
 I II III I/II I/III
I (≥ 0.523) 0.37 (0.008…0.81) -0.45 (-0.64…-0.26) -0.87 (-1.09 …0.65) 0.36 (0.15…0.57) 0.95 (0.42…1.49)
II (≥ 1.034) -1,04(-1.31…-0.77) 0.79 (0.15…1.43) -1.12 (-1.70…-0.54) 0.92 (0.15…1.69) -1.15 (-1.62…-0.67)
III (≥ 1.129) -0.59 (-1.37…-0.20) -0.29 (-0.97…-0.39) 0 (0…0) -0.27 (0…0) 1.55 (0.31…2.79)
N (≥ 0.259) -0.73 (-0.84…-0.61) -0.11 (-0.24…0.03) -1.19 (-1.33…1.05) 0.09 (0.0004…0.18) -1.08 (-1.27…-0.89)
A (≥ 0.902) -0.23 (-1.01…0.54) 0.12 (-0.33…0.57) -0.56 (-0.98…-0.14) 0.05 (0.17…0.28) 2.37 (1.58…3.16)
* Cat groups: I, cats infected with Toxoplasma gondii clonal type I (n=17); II, cats infected with T. gondii clonal type II (n=3); III, cat infected with T. gondii clonal type III (n=1);
N, naturally T. gondii-infected cats (n=86); A, cats infected with non-canonical T. gondii types (n=7); ** Peptide groups: I, II, or III, peptides with T. gondii type I, II, or III
specific amino acid (aa) sequences; I/II, peptides with aa sequences specific for both, type I and II; I/III, peptides with aa sequences specific for both, type I and III; CI:
confidence interval; CN-MSIV: Cut-off normalized mean reaction values (reaction value – cut-off value = CN-MSIV); In bold: statistically significant higher mean of CN-MSIVs
according to ANOVA/LSD Post-Hoc-Test
doi: 10.1371/journal.pone.0080213.t002
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Estimation of the prevalence of positive peptide reactions by
log-linear modelling showed a statistically significant
overrepresentation of clonal type II- (Pearson residuals > 3, p-
value < 0.01) as well as clonal type I/II-specific peptide
reactions (Pearson residuals > 1, p-value < 0.1). In contrast,
reactions against peptides with clonal type I- or III-specific
sequences were underrepresented (Pearson residuals < -1, p-
value < 0.1) in cats infected with clonal type II T. gondii (Figure
2 [B]).
Clonal type III-infected cat.  The significantly highest CN-
MSIVs of a serum from a cat infected with clonal type III T.
gondii were observed in peptides with type I/III-specific aa
sequences, followed by the CN-MSIVs observed in the group
of clonal type III-specific peptides (Table 2, ANOVA, LSD ≥
1.128604, p-value < 0.05). The highest CN-MSIVs were
observed in the peptides GRA3-I/III-189, GRA3-I/III-28 and
GRA6-I/III-220. All peptides with clonal type III-specific
sequences were recognized as positive, but reactions were
close to the peptide-specific cut-offs (Figure 3 [A]).
Four peptides with heterologous specificity (GRA7-II-225,
GRA6-I-216 and SAG2A-II-131) were also recognized by the
serum. However, the MSIVs recorded for these peptides were
markedly lower (Figure 3 [A]) as compared to peptides with a
homologous aa sequence specificity.
Since only one reference serum specific for clonal III was
available, it was not possible to establish a statistically
Figure 1.  In Toxoplasma gondii type I-infected cats reactions against type I, I/II and I/III specific peptides are strongest and
are overrepresented in number.  Intensities (MSIVs) by which clonal type I-infected cats reacted with individual peptides were
analyzed using ANOVA and the Least Significant Difference (LSD)-Post-Hoc-Test (A). Whiskers represent 95% confidence intervals
of the means of MSIV (bars). The differences between the means of MSIVs were regarded as statistically significant, when they
were equal or higher than the LSD values. Different letters above the whiskers indicate significant differences between the mean
intensities in the LSD-Post-Hoc-Test.
To evaluate whether positive or negative serum reactions against clonal type-specific peptide cohorts were over- or
underrepresented in cats infected with T. gondii clonal type I, a log-linear model analysis was used and the results presented in a
mosaic plot (B). The size of each box in the mosaic plot corresponds to the observed frequencies of positive (Pos) and negative
(Neg) peptide reactions as well as the number of analyzed peptides within each peptide cohort. Pearson residuals represent
standardized deviations of observed from expected values. The Pearson residuals 0-2 with solid blue line indicate that the number
of positive or negative reactions is higher, but not statistically significantly higher than expected (Pearson chi-squared p-value <
0.1). Blue scale shadings suggest the statistically significant rejection of the null hypothesis, i.e. overrepresentation of reactions
against particular peptide groups (Pearson residuals (>2), Pearson chi-squared p-value < 0.05). Dashed red lines indicate an
underrepresentation of positive or negative peptide reactions which is not statistically significant. Red scale shadings suggest a
statistically significant rejection of the null hypothesis, i.e. underrepresentation of peptide reactions within the analyzed peptide
group (Pearson residuals (<-2) Pearson chi-squared p-value, 0.05).
doi: 10.1371/journal.pone.0080213.g001
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significant log-linear model for the prevalence of positive or
negative peptide reactions. Nevertheless, clonal type III- as
well as I/III-specific positive peptide reactions were
quantitatively overrepresented (Pearson residuals > 1, p-value
< 0.1), whereas positive reactions from clonal type I-, II- and
I/II-specific peptides were underrepresented (Figure 3 [B]).
Clonal type II-specific reactions dominate in naturally
infected cats
Sera collected from naturally T. gondii seropositive cats from
Germany (n=86) showed the strongest reactions (i.e. highest
CN-MSIVs) with peptides of aa sequences homologous to
clonal type II (II and I/II) as compared to reactions with peptides
of clonal type I- or III-specific aa sequences (Table 2; ANOVA,
LSD ≥ 0.259, p-value < 0.05).
The highest CN-MSIVs were observed for peptide SAG2A-
II-93 followed by SAG2A-II-135 and GRA7-II-225, which were
both also recognized by significantly higher positive CN-MSVIs
as compared to most remaining peptides, including GRA5-
III-34 and GRA7-I/II-193 and GRA6-I/III-220 (ANOVA, LSD ≥
0.454, p-value < 0.05) (Figure 4 [A]).
SAG2A-II-93 was the peptide recognized by the highest
number of T. gondii seropositive field sera (n=67, [77.9%]),
followed by SAG2A-II-135 (n=60 [69.7%]), GRA7-II-225 (n=40,
[46.5%]) and SAG2A-II-131(n=26, [30.2%]) (Table S4).
Log-linear model analysis revealed that reactions with
peptides displaying clonal type II-specific aa sequences (II, I/II)
were statistically significantly overrepresented (Pearson
residuals > 3.1, Chi-squared p-value < 0.01) (Figure 4 [B]),
whereas positive clonal type I- or III-specific peptide reactions
were significantly underrepresented (Pearson residuals < 2.1,
Chi-squared p-value < 0.05 (Figure 4 [B]).
Cats infected with non-canonical T. gondii recognized
mainly type I/III specific peptides
Cats infected with non-canonical T. gondii showed the
strongest reactions, i.e. the highest mean CN-MSIVs, against
peptides presenting aa sequences specific for type I and III
(Table 2; type I/III peptides). Statistically significant differences
were not observed among the clonal type I-, II- ,III- and I/II-
specific peptide groups (Table 2; ANOVA, LSD ≥ 0.9, p-value <
0.05).
Peptides GRA3-I/III-28 and SAG2A-I/III-131 were recognized
with the highest mean CN-MSIVs. Lower CN-MSIVs were
observed in SAG2A-II-131, GRA3-I/III-189, GRA5-I-41 and
GRA6-I/III-220; however, the differences in reaction intensities
Figure 2.  In Toxoplasma gondii type II-infected cats reactions against type II and I/II specific peptides are strongest and
overrepresented in number.  Intensities (MSIVs) by which clonal type II-infected cats reacted with individual peptides were
analyzed using ANOVA and the Least Significant Difference (LSD)-Post-Hoc-Test (A). To evaluate whether positive or negative
serum reactions against clonal type-specific peptide cohorts were over- or underrepresented in cats infected with T. gondii clonal
type II, a log-linear model analysis was used and the results presented in a mosaic plot (B).
Detailed explanations of [A] and [B] are provided in Figure 1.
doi: 10.1371/journal.pone.0080213.g002
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were not statistically significant when compared with those
against GRA3-I/III-28 and SAG2A-I/III-131. The remaining
peptides were recognized in average by significantly lower
index values (LSD ≥ 1.704, p-value < 0.05) (Figure 5 [A]).
GRA3-I/III-189 peptide was recognized by all sera (100%),
while 6 of 7 sera (86%) detected SAG2A-I/III-131and GRA3-I/
III-28 (Table S4).
Log-linear analysis of positive and negative peptide reactions
among clonal type-specific peptides revealed that reactions
with peptides containing sequences specific for both, type I and
III, were statistically significantly overrepresented (Pearson
residuals >3, p-value < 0.01), whereas clonal type I- and III-
specific peptide reactions were underrepresented (Pearson
residuals <-1, p-value < 0.1). No significant differences were
observed in the frequency of positive and negative reactions
among clonal type II- and I/II-specific peptide cohorts (Pearson
residuals -1< 0 < 1, p-value > 0.1) (Figure 5 [B]).
Naturally seropositive cats group together with type II-
infected cats in a XY-fused supervised Kohonen
network
Each tested serum recognized several peptides with a
different MSIV. To detect similarities among the tested sera in
the recognized peptide patterns, explorative analysis of the
data using a XY-fused supervised Kohonen network (XYF-
SKN) was performed.
The Y-map of SKN is presented in the Figure 6 [A], where
sera from five cat groups (i.e. three groups consisting of
reference sera for type I, II or III, one group of sera from non-
canonical type-infected cats and one group of sera from cats
naturally infected with T. gondii) are clustered according to their
similarity in peptide reactivity.
XYF-SKN classification analysis of serum-peptide reactions
predicted three cat groups consisting mainly of animals
infected with non-canonical and clonal type III T. gondii (A,
red), clonal type I (I, green) or with natural infection (N, blue)
(Figure 6 [A], [B]). Group N (Figure 6 [A], [B], blue) consisted
of six nodes (1-3 and 6-8) with 85 (98.8%) sera of naturally
infected cats and of all three sera from cats infected with T.
gondii type II. Three sera from cats infected with T. gondii
clonal type I and two sera collected from cats infected by non-
canonical T. gondii fell also into this group. The second group I
(Figure 6 [A], [B], green) consisted of a single grid node (5)
with 11 type-I-sera and one serum from a naturally infected cat.
The third group A (Figure 6 [A], red) consisted also of a single
grid node (4) with five sera from cats infected with non-
canonical T. gondii strains, three sera from type I-infected cats
and one serum from a type I infected cat.
Figure 3.  In a Toxoplasma gondii type III-infected cat type III and I/III specific peptides were recognized strongest and were
overrepresented in number.  Intensities (MSIVs) by which clonal type III-infected cats reacted with individual peptides were
analyzed using ANOVA and the Least Significant Difference (LSD)-Post-Hoc-Test (A). To evaluate whether positive or negative
serum reactions against clonal type-specific peptide cohorts were over- or underrepresented in a cat infected with T. gondii clonal
type III, a log-linear model analysis was used and the results presented in a mosaic plot (B).
Detailed explanations of [A] and [B] are already given in Figure 1.
doi: 10.1371/journal.pone.0080213.g003
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Almost all sera from cats infected by clonal types I (n=11)
and III (n=1) clustered in one unit (grid node 5) (Figure 6 [C]).
Two of the remaining type I sera were grouped together with 15
sera obtained from naturally seropositive cats into grid node 1
(Figure 6 [A], [C]). The remaining type I serum and four sera
from naturally seropositive cats were placed in grid node 2
(Figure 6 [A], [C]).
The serum of a type II infected cat clustered in grid node 3
together with 8.1% (n=7) of the sera obtained from naturally
seropositive cats sampled in Germany (Figure 6 [A], [C]). The
second type II-specific serum was grouped with 36.04% (n=31)
of the sera obtained from naturally-seropositive cats sampled in
Germany and two sera from cats infected with non-canonical T.
gondii in grid node 6 (Figure 6 [A], [C]). The third type II serum
was sorted together with 27.9% (n=24) of T. gondii-positive cat
field sera into grid node 7 (Figure 6 [A], [C]).
The remaining 5 of 7 sera collected from cats infected with
non-canonical T. gondii clustered separately in grid node 4
together with one serum of a clonal type III-infected cat and
three sera from cats infected with T. gondii clonal type I (Figure
6 [A], [C]).
In the grid node 8 only sera from naturally-seropositive cats
(n=4) were present (Figure 6 [A], [C]).
Discussion
Several studies conducted with human and murine sera have
shown that the antibody response against T. gondii is partially
specific for the clonal type of the parasite [10,31]. Based on
these findings non-invasive typing methods using synthetic
peptides or recombinant polypeptides in serotyping ELISAs or
microarrays were developed and used to investigate the
presence of antibodies to specific clonal types of T. gondii in
infected humans and animals [10,27,30,31,43,73]. To our
knowledge, there is no published information about a clonal
type-specific antibody response to T. gondii and serotyping in
cats, although the cat plays a major role as an important
definitive host in the epidemiology of the T. gondii infection.
The availability of sera from individuals with a known clonal
type of T. gondii infection is a prerequisite for developing
serotyping tools. Since sera from humans with a known clonal
type of T. gondii infection are very rare, sera from infected mice
were used to evaluate peptides that were possibly suitable for
serotyping with human sera [10]. Fortunately, we were in a
position to use a few sera from experimentally infected cats to
evaluate candidate peptides, i.e. to identify those peptides that
showed optimal specificity for serotyping canonical type T.
gondii infections.
Figure 4.  In naturally Toxoplasma gondii seropositive cats strongest reactions were observed against type II and I/II-
specific peptides and reactions against these peptides were overrepresented.  Intensities (MSIVs) by which naturally infected
cats reacted with individual peptides were analyzed using ANOVA and the Least Significant Difference (LSD)-Post-Hoc-Test (A). To
evaluate whether positive or negative serum reactions against clonal type-specific peptide cohorts were over- or underrepresented
in naturally T. gondii-infected cats, a log-linear model analysis was carried out and results presented as mosaic plot (B).
Detailed explanations of [A] and [B] are already given in Figure 1.
doi: 10.1371/journal.pone.0080213.g004
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Some of the experimentally infected cats, whose sera were
made available for the present study, had originally been used
for oocysts production and were therefore orally inoculated with
tissue cysts. It must be expected that this way of infection did
not only induce the development of intestinal stages like
schizonts and later-on gamonts, but also caused the
establishment of extra-intestinal stages such as tachyzoites
and bradyzoites [39]. As a consequence, cats shedding
oocysts often develop a long-lasting humoral immune response
against tachyzoites and bradyzoites. The resulting antibodies
could be used for serotyping in order to determine the clonal
type of T. gondii infection in individual cats. Since
seroconversion to T. gondii is usually permanent, typing is not
only possible in cats actually shedding oocysts (in Europe only
a small proportion of less than 1% of all cats [21]) but also in
the vast majority of animals that became infected with T. gondii
in the past but failed to excrete oocysts or were not checked for
oocyst shedding when they were bled. Serotyping may
therefore allow a less biased view on the clonal types of T.
gondii circulating in a cat population as compared to
genotyping, which is necessarily restricted to a very small
proportion of the cat population.
In the present study, we analyzed a total of 101 T. gondii
polymorphic peptides, i.e. peptides with clonal type specific aa
sequences to identify molecules suitable for serotyping of T.
gondii in cats. Sera from experimentally infected cats or cats,
for which the type of the infecting T. gondii had been
determined, as well as seronegative cats were used to select
appropriate peptides, i.e. peptides with optimal specificity and
sensitivity. From these 101 peptides, 54 had previously been
characterized for T. gondii serotyping in humans [10]. Fifteen of
the 54 peptides taken from the literature were shown to react in
a clonal type-specific manner with cat sera. Another 47
peptides were selected for the present study using a
bioinformatical approach that employed a propensity scale
method [74]. Twenty-one of 47 (44.7%) peptides predicted by
this approach revealed diagnostic capability (AUC value ≥ 0.7
in ROC analysis). However, only 9 of these 47 (19.1%)
peptides were recognized in a clonal type-specific manner by
cat sera. GRA5 derived peptides did not meet all the criteria of
the propensity scale method. In spite of this, the success of a
correct prediction of linear B-cell epitopes was similar in GRA5
peptides; i.e., 5 of 9 (55.6 %) GRA5 peptides revealed
diagnostic capability and only 2 of 9 (22.2%) GRA5 peptides
were recognized in a clonal type-specific manner. This
Figure 5.  In cats infected with non-canonical Toxoplasma gondii strongest reactions were observed against type I/III
specific peptides and the number of reactions against these peptides were overrepresented.  Intensities (MSIVs) by which
non-canonical type-infected cats reacted with individual peptides were analyzed using ANOVA and the Least Significant Difference
(LSD)-Post-Hoc-Test (A). To evaluate whether positive or negative serum reactions against clonal type-specific peptide cohorts
were over- or underrepresented in cats infected with atypical T. gondii, a log-linear model analysis was used and the results
presented in a mosaic plot (B).
Detailed explanations of [A] and [B] are already given in Figure 1.
doi: 10.1371/journal.pone.0080213.g005
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illustrates an underperformance of the propensity scale
approach to select appropriate peptides and corroborates the
results of previous studies [75-77].
Interestingly, we found that peptides previously described as
suitable for T. gondii serotyping in humans and mice [10,30,78]
could also be used with feline sera. Obviously, such peptides
contain clonal type-specific epitopes that are recognized by
antibodies produced by a broad variety of vertebrate species
including humans, mice and cats, and possibly also other
intermediate hosts of T. gondii. In addition, these results show
Figure 6.  Naturally Toxoplasma gondii seropositive cats and cats with a known clonal type II infection recognized similar
peptide patterns.  To explore whether there are particular patterns of anti-peptide reactions among all serologically positive T.
gondii cat sera, a XY-fused Selforganizing Kohonen Network analysis (XYF-SKN) was performed. Figure (A) presents the clustering
of various groups of T. gondii positive cat sera in a Y-map. Most of the sera derived from cats infected with non-canonical T. gondii
types (A), infected by clonal types I, II or III (I, II, or III), or naturally infected cats (N) clustered in the grid nodes 1 to 8 either together
(type III- and atypical type-infected [node 4] as well as the type II and naturally infected cats [nodes 1 to 3 and 6 to 8]) or separately
(cats infected with type I T. gondii [node 5]). Three cat groups were predicted using XYF-SKN, e.g. a cat group infected with non-
canonical and type III T. gondii strains (A), a clonal type I infected group (I) and a naturally-infected cat group (N). Predicted cat
groups are presented by different background colours of grid nodes, e. g A by red, I by green and N by blue. Figure (B) shows the
number of group-specific sera within predicted clusters (A, I and N), further confirming that sera of naturally infected cats clustered
mainly with type II reference sera. Figure (C) shows the number of group-specific sera within eight grid nodes in Figure (A).
doi: 10.1371/journal.pone.0080213.g006
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that resources available in both, human and veterinary
medicine could be commonly used to improve sensitivity and
specificity of serological tests as e.g. tests for serotyping.
However, a large number of peptides showed a low clonal
type-specificity in cats – although their aa sequences had
indicated clonal type specificity – and were therefore not
included into the final serotyping peptide panel. Similar results
were obtained when peptides with polymorphic epitopes were
validated with mouse sera [10]. The low type-specificity of
particular peptides may be explained by a strong immune-
reactivity in the non-polymorphic parts of these peptides.
Further refinement of such peptides, e.g. by varying the length
of their non-polymorphic portions may help to achieve type-
specific reactivity [10].
Our experiments led to the detection of 24 peptides deemed
suitable for typing canonical clonal types of T. gondii infection
in cats using sera obtained from these animals.
There was no reference serum from cats infected with
canonical clonal types that failed to recognize peptides
presenting epitopes with a homologous specificity for those T.
gondii types the cats were infected with. We thus believe that
this panel of polymorphic, clonal type-specific peptides can be
used for epidemiological studies in cats in areas, where
canonical types of T. gondii prevail, i.e. in Europe and North
America. We applied the peptide panel to determine the
distribution of the clonal types of T. gondii infection among
naturally seropositive cats from Europe based on DNA from
oocysts from naturally infected cats [20,21]. Genotyping and
serotyping could therefore be compared for cats from the same
region.
Serotyping results in naturally seropositive cats revealed that
clonal type II-specific peptides were recognized by the
significantly highest MSIVs as compared to peptides with other
sequence specificities. Moreover, type II-specific serum-
peptide reactions were significantly overrepresented as
compared to reactions with the remaining peptide groups.
Explorative data analysis using XYF-SKN prediction revealed
that 98.8% of sera (85/86) obtained from naturally seropositive
cats clustered in one group and recognized similar peptide
patterns as cats with a known T. gondii type II-infection, i.e.
were assorted together with sera from in a single group (N) but
into 6 different nodes suggesting slight differences in which
peptides were recognized. Four peptides with type II specific
aa sequences recognized by field sera were also recognized
by cats with a confirmed or experimental T. gondii type II
infection. However, in case of the peptide SAG2A-II-93 the
reactions in cats with confirmed or experimental type II
infection were only close to the cut-off while field sera reacted
strongly with SAG2A-II-93. Differences in the expression of
SAG2A between field and laboratory strains used for
experimental infection in the present study, differences in the
stage of infection between field and laboratory cats or host
genetic factors could have contributed to this observation.
Therefore, based on the serotyping results it is not unlikely that
the majority of naturally seropositive cats from Germany were
infected with type II T. gondii, which is in accord with
genotyping results obtained with DNA from oocysts shed by
cats [20,21] and with T. gondii serotyping results performed
with human sera from Germany [30].
Although in the XYF-SKN analysis naturally seropositive cats
were mainly assorted to nodes containing sera from type II-
infected cats, also a few sera from cats infected with clonal
types I (n=3) or cats infected with non-canonical T. gondii types
(n=2) were assorted to these nodes. In addition, a few sera
from cats experimentally infected with type I (3/16), type III
(n=1/1) and atypical (5/7) strains clustered together in a single
node in the XYF-SKN prediction, i.e. could not clearly
separated from each other by serotyping. These results show
the limitations of serotyping. As documented in Table S4, the
specificity of some peptides for typing purposes is limited and it
can be hypothesized that false positive reactions may occur in
non-polymorphic, but also in the polymorphic (i.e. clonal type
specific) regions of the peptides. These unspecific reactions in
addition to a low number of reactive peptides may have
attributed to the failure to differentiate between cats infected
with canonical and atypical strains. In addition, it does not
seem to be not possible to identify mixed infections
unambiguously, as reactions with peptides with different type-
specificities may have been caused by infections with more
than one type (i.e. by mixed infections or superinfection) or by
infection with an atypical strain.
Previous genotyping results suggested that mixed or
superinfections with more than one canonical type of T. gondii
can occur in cats under natural conditions [23,35], but there is
no information on the expected frequency. It can be
hypothesized that mixed or superinfection may be more likely
in areas were more than one of the canonical types of T. gondii
coexist. Since infection in cats seem to be clearly age-
dependent [79], limiting serotyping to young cats (≤ 2 years of
age) might be suitable to reduce the risk of misclassification
due to mixed or superinfection in epidemiological studies.
Sousa et al. (2008) [29] reported on the serotyping in
humans infected with non-canonical T. gondii types from Africa
and South America by using peptides derived from clonal type
II- and I/III-specific polymorphic GRA6 protein regions. Most of
these human sera recognized mainly a clonal type I/III GRA6
peptide [29]. In the present study, we serotyped cats infected
with non-canonical T. gondii from Brazil (TgCatBr1, 2, 5) and
North America (TgBbUS1 and TgGoatUS6). Interestingly,
these sera also recognized clonal type I/III-specific peptides
with the significantly highest mean MSIVs and the number of
positive type I/III peptides reactions were significantly
overrepresented in these sera. Strong reactions with individual
peptides specific for clonal types I, II or III were also observed.
The strong IgG response against type II-, or type I/III-specific
peptides in cats infected with non-canonical T. gondii may
indicate that especially proteins with epitopes common in type
II, or I/III are expressed by these non-canonical strains. Since
sequences of proteins from these atypical T. gondii isolates are
not available, it was not possible to test this hypothesis.
Although cats infected with atypical T. gondii reacted strongly
with peptides specific at the same time for type I and III (i.e.
type I/III peptides) most of these cats showed peptide patterns
different from cats infected with type I and type II (Figure 6).
This finding provides confidence that our serotyping assay
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would have been able to detect during field study a population
of cats with non-canonical T. gondii infection. However, both,
mixed infections and infections with non-canonical or atypical
strains (as shown in the present study) may cause an antibody
response reactive with single peptides containing epitopes
specific for canonical types of T. gondii. Therefore, serotyping
results have to be analyzed with care to avoid
misinterpretation. We therefore propose serotyping as an
epidemiological tool for typing in areas where canonical T.
gondii-infections prevail, but not as a tool for typing individual
cats.
In conclusion, in the present study we showed that cats
mount an antibody response that is specific for the T. gondii
clonal type and identified 24 peptides suitable for T. gondii
serotyping in cats. Our results suggest that most T. gondii
seropositive cats in Germany are infected with type II T. gondii.
This finding is in accord with previous findings reporting a
predominance of type II T. gondii in oocysts shed by cats in
Germany [20] and with T. gondii serotyping in humans from
Germany, which also suggested that type II infections prevailed
[30]. Further studies with larger numbers of well-defined sera
may help to improve the evaluation of polymorphic peptides
and to identify more peptides suitable for T. gondii serotyping in
cats.
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